Victory Capital Management
MRSN

Victory Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Victory Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-414
Closed -$3.56K – 2527
2025
Q1 		$3.56K Sell
414
-14
-3% -$216 ﹤0.01% 2470
2024
Q4 		$15.3K Sell
428
-30
-7% -$1.55K ﹤0.01% 2457
2024
Q3 		$21.7K Sell
458
-17
-4% -$750 ﹤0.01% 2435
2024
Q2 		$23.9K Sell
475
-8
-2% -$578 ﹤0.01% 2420
2024
Q1 		$54.1K Sell
483
-26
-5% -$2.58K ﹤0.01% 2369
2023
Q4 		$29.5K Buy
+509
New +$20.5K ﹤0.01% 2480
2022
Q3 		– Sell
-501
Closed -$58K – 2744
2022
Q2 		$58K Buy
501
+91
+22% +$8.56K ﹤0.01% 2535
2022
Q1 		$36K Buy
+410
New +$47.9K ﹤0.01% 2616
2021
Q2 		– Sell
-755
Closed -$305K – 2796
2021
Q1 		$305K Sell
755
-427
-36% -$207K ﹤0.01% 2388
2020
Q4 		$786K Buy
1,182
+403
+52% +$224K ﹤0.01% 1886
2020
Q3 		$362K Buy
779
+414
+113% +$209K ﹤0.01% 2093
2020
Q2 		$213K Buy
365
+145
+66% +$49.5K ﹤0.01% 2279
2020
Q1 		$32K Buy
+220
New +$38.4K ﹤0.01% 2655
2019
Q4 		– Sell
-258
Closed -$10K – 3018
2019
Q3 		$10K Buy
+258
New +$18.8K ﹤0.01% 3260
2018
Q1 		– Sell
-2,317
Closed -$952K – 1880
2017
Q4 		$952K Buy
2,317
+229
+11% +$99.9K ﹤0.01% 1231
2017
Q3 		$903K Sell
2,088
-72
-3% -$28.4K ﹤0.01% 1230
2017
Q2 		$754K Buy
+2,160
New +$747K ﹤0.01% 1240

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Victory Capital Management's MRSN Position: Q2 2025 in Review

Victory Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 414 shares — an estimated $3.56K sold.

Victory Capital Management first reported a position in MRSN in Q2 2017 and held it in 17 quarters. The position peaked at $952K in Q4 2017. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Victory Capital Management reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Victory Capital Management sold 414 Mersana Therapeutics shares in Q2 2025, an estimated $3.56K.
  • Victory Capital Management first reported a position in Mersana Therapeutics in Q2 2017 and held it in 17 quarters.
  • Victory Capital Management's Mersana Therapeutics position peaked at $952K in Q4 2017.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Victory Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.